LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
LIGAND PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$297.28+1.74 (+0.59%)
Close on Oct 19, 2026
- Market cap
- $6.49B
- P/E (TTM)
- 31.6
- Dividend yield
- –
LIGAND PHARMACEUTICALS INC revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalties | $161.00M | $108.77M | $84.96M | $72.91M | $48.93M | $33.80M | $46.98M | $128.56M | $88.69M | $59.42M | 60.1% | +48.0% |
| Revenue from intangible royalty assets | $132.53M | $95.33M | $83.91M | $72.53M | – | – | – | – | – | – | 49.4% | +39.0% |
| Contract revenue | $66.87M | $27.48M | $17.98M | $18.84M | $28.37M | $19.81M | $41.82M | $93.77M | – | – | 24.9% | +143.4% |
| Contract revenue and income | $66.87M | $27.48M | $17.98M | – | – | – | – | – | – | – | 24.9% | +143.4% |
| Income from Pelthos Transaction | $53.07M | $0 | $0 | – | – | – | – | – | – | – | 19.8% | – |
| Captisol | $40.21M | $30.88M | $28.37M | $104.50M | $164.25M | $109.96M | $31.49M | $29.12M | $22.07M | $22.50M | 15.0% | +30.2% |
| Captisol | $40.21M | $30.88M | $28.37M | $16.43M | $23.42M | $24.57M | – | – | – | – | 15.0% | +30.2% |
| Kyprolis | $35.53M | $38.38M | $35.64M | $30.12M | $27.47M | $25.16M | $25.05M | $21.69M | – | – | 13.3% | -7.4% |
| Filspari | $31.97M | $12.18M | $2.66M | $0 | – | – | – | – | – | – | 11.9% | +162.5% |
| Income from financial royalty assets | $28.47M | $13.44M | $1.05M | $385.00K | – | – | – | – | – | – | 10.6% | +111.7% |
| Qarziba | $23.74M | $11.12M | $0 | – | – | – | – | – | – | – | 8.9% | +113.5% |
| Rylaze | $13.35M | $13.74M | $13.52M | $8.80M | $2.42M | $0 | – | – | – | – | 5.0% | -2.9% |
| Other | $10.37M | $7.49M | $6.76M | $6.55M | $3.70M | $2.26M | $2.57M | $1.95M | – | – | 3.9% | +38.5% |
| Capvaxive | $10.06M | $626.00K | $0 | – | – | – | – | – | – | – | 3.8% | +1506.9% |
| Ohtuvayre | $9.76M | $833.00K | $0 | – | – | – | – | – | – | – | 3.6% | +1071.7% |
| Teriparatide injection | $8.15M | $8.22M | $11.06M | $15.79M | $5.26M | $0 | – | – | – | – | 3.0% | -0.9% |
| Vaxneuvance | $7.40M | $5.18M | $4.06M | $1.08M | – | – | – | – | – | – | 2.8% | +42.8% |
| Income | $6.99M | $1.94M | $0 | $0 | $634.00K | $119.00K | $6.20M | $78.20M | $13.67M | $10.57M | 2.6% | +259.5% |
| Contract revenue | $6.81M | $25.53M | $17.98M | $18.84M | $3.74M | $9.33M | $16.78M | $4.75M | – | – | 2.5% | -73.3% |
| Evomela | $5.94M | $8.68M | $10.21M | $10.20M | $10.08M | $6.38M | $5.17M | $5.66M | – | – | 2.2% | -31.5% |
| Other | $4.73M | $2.32M | $1.05M | – | – | – | – | – | – | – | 1.8% | +103.4% |
| License fees, milestones and other revenues | – | – | – | – | – | – | $41.82M | $93.77M | $30.35M | $27.05M | – | – |
| Milestone | – | – | $16.80M | $9.15M | $17.58M | $5.22M | $17.17M | $6.58M | $11.09M | $16.09M | – | – |
| Other | – | – | $1.40M | $6.11M | $6.41M | $5.14M | $1.67M | $4.25M | $5.59M | $387.00K | – | – |
| Promacta | – | – | – | – | – | – | $14.19M | $99.26M | – | – | – | – |
| Captisol - COVID | – | $0 | $0 | $88.07M | $140.83M | $85.39M | – | – | – | – | – | – |
| Contract revenue and income | – | $27.48M | $17.98M | $18.84M | – | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Ligand Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.